Abstract |
MUSTT and MADIT have clearly shown the survival benefit of an implantable cardioverter defibrillator (ICD) in patients with previous myocardial infarction, left ventricular ejection fraction < or = 0.40, and nonsustained ventricular tachycardia (VT), and who have had sustained VT induced at electrophysiology study. Progress in primary prevention of sudden cardiac death (SCD) depends on a concerted effort by clinicians to identify and appropriately treat MUSTT/MADIT-type patients; further research to more precisely define patient subgroups at risk for SCD and the willingness of industry to develop a lower priced ICD for prophylactic use are needed.
|
Authors | E N Prystowsky, S Nisam |
Journal | The American journal of cardiology
(Am J Cardiol)
Vol. 86
Issue 11
Pg. 1214-5, A5
(Dec 01 2000)
ISSN: 0002-9149 [Print] United States |
PMID | 11090794
(Publication Type: Comment, Comparative Study, Editorial, Review)
|
Topics |
- Clinical Trials as Topic
- Death, Sudden, Cardiac
(etiology, prevention & control)
- Defibrillators, Implantable
- Humans
- Multicenter Studies as Topic
- Randomized Controlled Trials as Topic
(methods)
- Risk Factors
- Tachycardia, Ventricular
(complications, therapy)
- Ventricular Fibrillation
(complications, therapy)
|